1pkg › Citations

Structure of a c-kit product complex reveals the basis for kinase transactivation.

Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE
J Biol Chem 278 31461-4 (2003)
Cited: 166 times
EuropePMC logo PMID: 12824176

Abstract

The c-Kit proto-oncogene is a receptor protein-tyrosine kinase associated with several highly malignant human cancers. Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth. Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors. We report on the phosphorylation state and crystal structure of a c-Kit product complex. The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops. These results provide key insights into the molecular basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.

Reviews - 1pkg mentioned but not cited (6)

  1. Novel approaches to treating advanced systemic mastocytosis. Gilreath JA, Tchertanov L, Deininger MW. Clin Pharmacol 11 77-92 (2019)
  2. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  3. Mechanism of activation and the rewired network: New drug design concepts. Nussinov R, Zhang M, Maloney R, Tsai CJ, Yavuz BR, Tuncbag N, Jang H. Med Res Rev 42 770-799 (2022)
  4. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Diwanji D, Thaker T, Jura N. IUBMB Life 71 706-720 (2019)
  5. Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia. Ezelarab HAA, Ali TFS, Abbas SH, Hassan HA, Beshr EAM. BMC Chem 17 73 (2023)
  6. Impact of structural biology and the protein data bank on us fda new drug approvals of low molecular weight antineoplastic agents 2019-2023. Burley SK, Wu-Wu A, Dutta S, Ganesan S, Zheng SXF. Oncogene 43 2229-2243 (2024)

Articles - 1pkg mentioned but not cited (44)



Reviews citing this publication (40)

  1. Regulation of protein kinases; controlling activity through activation segment conformation. Nolen B, Taylor S, Ghosh G. Mol Cell 15 661-675 (2004)
  2. Gastrointestinal stromal tumours: origin and molecular oncology. Corless CL, Barnett CM, Heinrich MC. Nat Rev Cancer 11 865-878 (2011)
  3. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Lennartsson J, Rönnstrand L. Physiol Rev 92 1619-1649 (2012)
  4. The tyrosine kinase network regulating mast cell activation. Gilfillan AM, Rivera J. Immunol Rev 228 149-169 (2009)
  5. The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu Rev Biochem 81 587-613 (2012)
  6. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Roskoski R. Biochem Biophys Res Commun 338 1307-1315 (2005)
  7. Molecular pathobiology of gastrointestinal stromal sarcomas. Corless CL, Heinrich MC. Annu Rev Pathol 3 557-586 (2008)
  8. Normal and oncogenic forms of the receptor tyrosine kinase kit. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Stem Cells 23 16-43 (2005)
  9. Juxtamembrane autoinhibition in receptor tyrosine kinases. Hubbard SR. Nat Rev Mol Cell Biol 5 464-471 (2004)
  10. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Reber L, Da Silva CA, Frossard N. Eur J Pharmacol 533 327-340 (2006)
  11. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN. Q Rev Biophys 42 1-40 (2009)
  12. Platelet-derived growth factors and their receptors: structural and functional perspectives. Chen PH, Chen X, He X. Biochim Biophys Acta 1834 2176-2186 (2013)
  13. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Dibb NJ, Dilworth SM, Mol CD. Nat Rev Cancer 4 718-727 (2004)
  14. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM. Biochim Biophys Acta 1834 1302-1321 (2013)
  15. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Heldin CH, Lennartsson J. Cold Spring Harb Perspect Biol 5 a009100 (2013)
  16. Therapeutic targeting of c-KIT in cancer. Ashman LK, Griffith R. Expert Opin Investig Drugs 22 103-115 (2013)
  17. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Masson K, Rönnstrand L. Cell Signal 21 1717-1726 (2009)
  18. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Cruse G, Metcalfe DD, Olivera A. Immunol Allergy Clin North Am 34 219-237 (2014)
  19. Signal transduction of oncogenic Flt3. Choudhary C, Müller-Tidow C, Berdel WE, Serve H. Int J Hematol 82 93-99 (2005)
  20. Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Verstraete K, Savvides SN. Nat Rev Cancer 12 753-766 (2012)
  21. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Jensen BM, Akin C, Gilfillan AM. Br J Pharmacol 154 1572-1582 (2008)
  22. Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit. Cheng M, Qin G. Prog Mol Biol Transl Sci 111 243-264 (2012)
  23. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Gounder MM, Maki RG. Cancer Chemother Pharmacol 67 Suppl 1 S25-43 (2011)
  24. Masitinib for the treatment of mild to moderate Alzheimer's disease. Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A. Expert Rev Neurother 15 587-596 (2015)
  25. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. Akin C. J Mol Diagn 8 412-419 (2006)
  26. Bioinformatics and variability in drug response: a protein structural perspective. Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB. J R Soc Interface 9 1409-1437 (2012)
  27. Gastrointestinal stromal tumors: past, present, and future. Kitamura Y. J Gastroenterol 43 499-508 (2008)
  28. Role and significance of c-KIT receptor tyrosine kinase in cancer: A review. Sheikh E, Tran T, Vranic S, Levy A, Bonfil RD. Bosn J Basic Med Sci 22 683-698 (2022)
  29. Novel approaches in the treatment of systemic mastocytosis. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Cancer 107 1429-1439 (2006)
  30. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model. Chan PM. Protein Cell 2 108-115 (2011)
  31. KIT mutations in mastocytosis and their potential as therapeutic targets. Gotlib J. Immunol Allergy Clin North Am 26 575-592 (2006)
  32. The SCF/c-KIT system in the male: Survival strategies in fertility and cancer. Cardoso HJ, Figueira MI, Correia S, Vaz CV, Socorro S. Mol Reprod Dev 81 1064-1079 (2014)
  33. Translational insights into gastrointestinal stromal tumor and current clinical advances. Hemming ML, Heinrich MC, Bauer S, George S. Ann Oncol 29 2037-2045 (2018)
  34. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Quintás-Cardama A, Jain N, Verstovsek S. Cancer 117 5439-5449 (2011)
  35. Cardiac stem cell research: an elephant in the room? Di Felice V, De Luca A, Colorito ML, Montalbano A, Ardizzone NM, Macaluso F, Gammazza AM, Cappello F, Zummo G. Anat Rec (Hoboken) 292 449-454 (2009)
  36. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Correll PH, Paulson RF, Wei X. Gene 374 26-38 (2006)
  37. Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. DiNitto JP, Wu JC. Crit Rev Biochem Mol Biol 46 295-309 (2011)
  38. Molecular response prediction in gastrointestinal stromal tumors. Cassier PA, Blay JY. Target Oncol 5 29-37 (2010)
  39. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Zhou S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z, Xiao S, Li B. Cell Commun Signal 22 153 (2024)
  40. Surgical resection in metastatic gastrointestinal stromal tumors. Choi EA, Feig BW. Curr Oncol Rep 9 303-308 (2007)

Articles citing this publication (76)



Quick links